Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE
Annovis Bio received an NYSE notice on October 29, 2026 that it is out of compliance with continued listing standards due to a 30-day average market cap of ~$48.4 million and a stockholders' deficit of ~$(4.3) million. The company must submit a compliance plan within 45 days; if NYSE rejects it or the plan fails during the 9-month cure period, delisting proceedings will begin. Trading below $0.10 could trigger accelerated delisting.
Key figures
- Cure period months
- 9
- Avg market cap 30day usd
- 48400000
- Plan submission deadline days
- 45
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.